Investing In New Antibiotic Research: Difficult Equation Discussed At World Investment Forum 25/10/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment The diminishing arsenal of efficient antibiotics to fight bacteria is a threat denounced by many, but investment in research and development of new antibiotics is seen as lagging. As the danger of getting back to a pre-antibiotic age is increasing, alternative ways of financing new antibiotics are being discussed. At the World Investment Forum this week, a panel looked into innovative means of investment, and ways to attract private investors to this field.
WHO Members Consider Possible Changes To Pandemic Influenza Framework 23/10/2018 by Catherine Saez, Intellectual Property Watch 1 Comment A hundred years ago, the influenza pandemic known as the “Spanish flu” infected one-third of the world population, and resulted in an estimated 50 million deaths. Last week, the World Health Organization held a consultation on possible changes to its 2011 agreement to prepare for the next pandemic influenza. Two major questions were on the table: whether to extend its agreement to seasonal influenza, and how to deal with pandemic influenza genetic information, which is increasingly used instead of biological samples of viruses.
WIPO’s Coordination Committee Seats And The Election For Next Director General 10/10/2018 by Catherine Saez, Intellectual Property Watch 1 Comment Developing country members are asking to have more representation in the World Intellectual Property Organization governing bodies, and the issue is taking on increased importance as one of the committees will play a key role in the election of the next WIPO director general in 2020.
US High Court To Confront Unique Copyright Issue 05/10/2018 by Steven Seidenberg for Intellectual Property Watch 1 Comment The US Supreme Court often decides momentous cases. And then there’s Fourth Estate Pub. Benefit Corp. v. Wall-Street.com. Many experts view this case as little more than a tempest in a teapot. However, the suit will resolve a legal dispute that has simmered for over 30 years, and it highlights some important copyright issues that are unique to the US.
The Global Multilateral Benefit-Sharing Mechanism: Where Will Be The Bretton Woods Of The 21st Century? 05/10/2018 by Intellectual Property Watch 2 Comments Joseph Henry Vogel writes: Bretton Woods is the name of a place and also of a system. Bretton Woods-the-place boasts the Mount Washington Hotel and majestic views of the White Mountains of New Hampshire. Bretton Woods-the-system is the set of financial rules drafted during an international conference held at the hotel from 1 to 22 July 1944 [1]. The system created monetary order and allowed postwar recovery. For economists, Bretton Woods signifies the system. Its success illustrates how economic thinking can penetrate the political sphere and make lasting change. John Maynard Keynes, the Darwin of economics, led the British delegation.
Interview With Miguel Ángel Margáin, Director General Of The Mexican Institute Of Industrial Property 01/10/2018 by William New, Intellectual Property Watch Leave a Comment Miguel Ángel Margáin, Director General of the Mexican Institute of Industrial Property, took office in early 2013, and was in Geneva for the annual World Intellectual Property Organization General Assemblies. William New of Intellectual Property Watch sat down with him for an interview. He spoke about achievements of the office during this administration, major amendments to adhere to global treaties and changes in the NAFTA, the introduction of geographical indications, and the ascendance of IP rights in Latin America.
Interview With The President Of Brazil’s Industrial Property Institute 27/09/2018 by William New, Intellectual Property Watch 1 Comment Luiz Otávio Pimentel is president of the National Institute of Industrial Property (INPI) of Brazil. In Geneva this week for the annual World Intellectual Property Organization General Assemblies he took time to sit down with Intellectual Property Watch’s William New. INPI is part of the Ministry of Industry, Foreign Trade and Services. On a breaking issue, Pimentel talked about the case in Brazil involving sofosbuvir, marketed as Sovaldi, Gilead’s effective medicine against hepatitis C that has been known for its exorbitant prices.
Interview With The Korea IP Office’s Acting Commissioner 27/09/2018 by Intellectual Property Watch Leave a Comment Korean Intellectual Property Office (KIPO) Acting Commissioner Kim Tae Man is attending the annual World Intellectual Property Organization General Assembly this week. In that context, he sat down with Intellectual Property Watch, and in a mutually prepared Q&A, he described some of KIPO’s policies and future plans, collaboration with WIPO, international partnerships, and regional efforts toward global harmonisation.
Why Follow-On Pharmaceutical Innovations Should Be Eligible For Patent Protection 21/09/2018 by Intellectual Property Watch 1 Comment Christopher M. Holman writes: Despite the important role of intellectual property rights in incentivizing innovation, the patenting of pharmaceutical innovation is frequently accused of impeding access to medicine. Criticism of the prevailing patent regime has focused in particular on patents directed towards follow-on pharmaceutical innovation, i.e., innovation that seeks to improve upon existing pharmaceuticals and their use in treating patients. Patents on follow-on innovation are often derided as “secondary” patents, with the implication that the underlying inventions are somehow lesser in nature than the subject matter claimed in “primary” patents, i.e., the drug active ingredient per se. While implicitly acknowledging the legitimacy of primary patents, critics of so-called secondary patents contend that patents on follow-on innovation allow drug innovators to “evergreen” their products, i.e., to extend the period of patent exclusivity beyond the expiration of any original patent on the drug active ingredient, and in doing so contribute to the high cost of drugs, thereby limiting the ability of patients to access the drugs upon which they have come to rely.
Analysis: Move To Contain Global Challenge By Ascending China At Play In Escalating Trade War Between Washington And Beijing 19/09/2018 by John Zarocostas for Intellectual Property Watch Leave a Comment The latest escalation in US-Sino trade tensions following the announcement by President Donald Trump on 17 September that the US will slap 10 percent punitive tariffs on $200 billion worth of Chinese goods imports effective on 24 September and increase them to 25 percent on 1 January 2019, and China’s counter-salvo announced on 18 September to impose tariffs of between 5 and 10 percent on $60 billion worth of US goods imports to kick in on 24 September may prove difficult to ease back from the brink.